ondansetron hydrochloride - Profile

What are the generic drug sources for ondansetron hydrochloride and what is the scope of freedom to operate?

Ondansetron hydrochloride is the generic ingredient in six branded drugs marketed by Accord Hlthcare, Am Regent, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Onesource Specialty, Pliva Hrvatska Doo, Qilu Pharm Hainan, Rising, Sagent Pharms, Sandoz, Sun Pharm Inds (in), Teva, Wockhardt Bio Ag, Sun Pharm Inds Ltd, Taro Pharms Ireland, Glaxosmithkline, Amneal Pharms, Aurobindo Pharma, Pharm Assoc, Taro, Apotex, Chartwell Molecules, Chartwell Rx, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hikma Intl Pharms, Ipca Labs Ltd, and Natco Pharma Ltd, and is included in seventy-two NDAs. Additional information is available in the individual branded drug profile pages.

There are two tentative approvals for this compound.

Summary for ondansetron hydrochloride

US Patents:	0
Tradenames:	6
Applicants:	38
NDAs:	72

Generic filers with tentative approvals for ONDANSETRON HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 2MG BASE/ML	INJECTABLE;INJECTION
		EQ 2MG BASE/ML	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ONDANSETRON HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOFRAN	Oral Solution	ondansetron hydrochloride	4 mg/5 mL	020605	1	2004-12-20

US Patents and Regulatory Information for ondansetron hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	INJECTABLE;INJECTION	206846-001	Jul 13, 2015	AP	RX	No	No
Am Regent	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	INJECTABLE;INJECTION	077582-001	Dec 26, 2006		DISCN	No	No
Apotex Inc	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	INJECTABLE;INJECTION	077368-001	Dec 26, 2006		DISCN	No	No
Avet Lifesciences	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	INJECTABLE;INJECTION	090424-001	Apr 16, 2010		DISCN	No	No

Expired US Patents for ondansetron hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	ZOFRAN PRESERVATIVE FREE	ondansetron hydrochloride	INJECTABLE;INJECTION	020007-003	Dec 10, 1993	4,753,789*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-003	Aug 27, 1999	5,344,658*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	INJECTABLE;INJECTION	020007-001	Jan 4, 1991	4,695,578*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-002	Dec 31, 1992	5,344,658*PED

Investment Scenario and Fundamentals Analysis for Ondansetron Hydrochloride

Last updated: February 19, 2026

What is Ondansetron Hydrochloride?

Ondansetron Hydrochloride is a serotonin 5-HT3 receptor antagonist primarily used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. It is marketed under brand names such as Zofran and is available in oral, injectable, and orally disintegrating tablet formulations. The drug was first approved by the U.S. Food and Drug Administration (FDA) in 1991 and remains a widely used antiemetic.

Market Overview and Revenue Drivers

The global market for Ondansetron Hydrochloride was valued at approximately USD 1.2 billion in 2022, with an expected compound annual growth rate (CAGR) of around 3.5% through 2027. The demand correlates directly with cancer treatment rates, increased acceptance in postoperative care, and expanded use in pediatric and outpatient settings.

Key Market Segments

Segment	Market Share (2022)	Growth Drivers
Oncology (Chemotherapy)	60%	Rising cancer prevalence, improved supportive care
Postoperative Nausea	25%	Growing surgical procedures, anesthesia practices
Radiotherapy-related Nausea	10%	Increasing radiotherapy treatments, rising cancer cases
Other (Off-label uses)	5%	Novel indications, clinical trial explorations

Competitive Landscape

Global sales are led by Pfizer's Zofran, which held an estimated 65% market share in 2022. Generic versions account for 30%, with remaining shares held by regional or hospital-branded products.

Key Players

• Pfizer (Zofran)
• Glenmark Pharmaceuticals (generic)
• Teva Pharmaceuticals (generic)
• Hikma Pharmaceuticals (generic)

Patent and Regulatory Data

Pfizer's primary patent expired in 2008, leading to proliferation of generics. Some formulations are under patent protection until 2025–2028 in select markets, influencing pricing and market share.

Regulatory and Pricing Environment

In the U.S., ondansetron is classified as an over-the-counter (OTC) medication in some formulations, but primarily prescription-based. Pricing strategies vary by region; generics have reduced prices, expanding access but shrinking margins for branded product manufacturers.

International Market Regulations

Emerging markets face regulatory delays and price pressure, impacting profitability. The drug's inclusion in WHO’s Essential Medicines List in 2011 supports global access initiatives, especially in low-income regions.

R&D and Patent Outlook

No recent new chemical entities (NCEs) of ondansetron are in advanced clinical trials. Focus shifts toward combination therapies, novel delivery methods (e.g., controlled-release formulations), and bioequivalent generics.

Patent landscape indicates no new patents on the chemical compound itself, but formulations and delivery methods might enjoy intellectual property protection until 2025–2030.

Pricing and Cost Considerations

In the U.S., branded ondansetron tablets cost approximately USD 10–15 per dose, while generics retail for USD 2–5. In developing countries, prices drop below USD 1 per dose, with government procurement policies affecting volumes and profitability.

Investment Considerations

• Market Maturity: The market is mature with stable demand aligned with cancer and surgery rates.
• Patent Expiry: Branded market share declining due to patent expiry; opportunities exist in generics and biosimilars.
• Regulatory Environment: Divergent regional regulations influence market access; generic entry is often facilitated.
• Pricing Pressure: Rising competition pushes margins downward, especially in price-sensitive markets.
• Growth Opportunities: Combination therapies, new formulations, and expanding access in low-income countries.

Entry and Exit Strategies

• Investing in generic manufacturers could capitalize on the patent cliff.
• Developing innovative formulations—such as sustained-release or pediatric-friendly forms—may command premium pricing.
• M&A activity is prevalent, with larger firms acquiring smaller innovators to expand portfolios.

Risks

• Regulatory delays in specific markets.
• Intense price competition from generics.
• Slow adoption of new formulations or combinations.
• Price suppression due to healthcare reforms and reimbursement policies.

Key Takeaways

• Ondansetron Hydrochloride remains a stable, mature market with predictable demand.
• Patent expiration and generic competition pressure margins.
• Growth pivots to formulations, off-label uses, and expanding access in emerging markets.
• R&D investments should target delivery improvements and combination therapies.
• Financial viability depends on regulatory dynamics and pricing strategies across regions.

Five FAQs

1. What are the principal drivers of ondansetron demand?
The primary drivers include increased cancer treatment rates, rise in surgical procedures, and expanded use of radiotherapy.

2. How does patent expiration impact market competition?
Patent expiry enables generic manufacturers to enter the market, lowering prices and reducing profitability for branded products.

3. Are there ongoing R&D efforts for ondansetron?
R&D focuses on new formulations, combination therapies, and delivery mechanisms rather than chemical innovation, as the molecule itself is off-patent.

4. What regional factors influence profitability?
Stringent regulations, reimbursement policies, and price controls in developed markets contrast with limited regulations but lower prices in emerging markets.

5. What future growth opportunities exist?
Opportunities lie in developing controlled-release forms, pediatric-friendly options, and expanding availability in low-income countries through partnerships.

---

References

[1] EvaluatePharma. (2022). Pharmaceuticals Market Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Ondansetron NDA approval documentation.
[3] IMS Health. (2022). Global Oncology Supportive Care Drugs Market Report.
[4] World Health Organization. (2011). Essential Medicines List.
[5] Statista. (2022). Global antiemetic drug sales data.